NAD+: The Molecule That Powers Every Cell in Your Body, Explained Simply

NAD+ stands for nicotinamide adenine dinucleotide — a name that accurately communicates that this molecule is made of nicotinamide (a form of vitamin B3) combined with adenine and a sugar phosphate backbone. It is a coenzyme, meaning it is not an enzyme itself but a molecule that enzymes require in order to function.

Think of NAD+ as the fuel gauge for your cellular engine. Without sufficient NAD+, the metabolic engines that power your cells — the mitochondria — cannot run the reactions they need to run. The electron transport chain, which is how mitochondria convert food into ATP, absolutely requires NAD+ as a cofactor. When NAD+ is depleted, the chain slows and energy production declines.

NAD+ exists in oxidized form (NAD+) and reduced form (NADH). The conversion back and forth between these two forms is central to cellular energy metabolism. Hundreds of metabolic reactions use this NAD+/NADH cycling — it is one of the most fundamental molecular processes in all of biology.

Human tissue NAD+ levels peak in the twenties and decline progressively from there. By middle age, NAD+ levels in many tissues have dropped by roughly 50 percent compared to young adulthood. By late life, the decline is more severe. This has been measured directly in muscle, skin, liver, and brain tissue from human subjects across age groups.

The decline has multiple causes. PARP enzymes — which repair DNA damage — consume NAD+ whenever they activate, and DNA damage accumulates with age, meaning more NAD+ is consumed for repair. CD38, an enzyme involved in immune signaling, also consumes NAD+ and becomes more active with age. Meanwhile, the biosynthetic pathways that produce NAD+ in cells — particularly the salvage pathway that recycles NAD+ precursors — become less efficient.

The net result is a progressive decline that researchers describe as an "NAD+ crisis" — a shortage of a molecule that hundreds of cellular processes depend on, occurring precisely at the stage of life when these processes are already under increasing stress.

Sirtuins represent one of the most studied NAD+ applications in aging research. Sirtuins are a family of seven enzymes (SIRT1 through SIRT7) that regulate DNA repair, inflammatory signaling, metabolic efficiency, and cellular stress responses. All seven sirtuins require NAD+ to function — they consume NAD+ as they perform their regulatory activity. When NAD+ levels fall, sirtuin activity falls with it.

PARP enzymes are the second major class. These are the DNA repair machinery — they scan for and fix DNA strand breaks and base modifications that occur constantly in every cell. Each repair event consumes NAD+. With age, as DNA damage accumulates, PARP activity increases, NAD+ consumption increases, and the already declining NAD+ pool is further depleted. This creates a downward spiral: less NAD+, less sirtuin activity, less metabolic efficiency, more oxidative damage, more DNA damage, more PARP activation, less NAD+.

Direct energy metabolism is the third and most fundamental role. NAD+ is the central electron carrier in the metabolic conversion of nutrients to ATP. Every molecule of glucose and fatty acid that your mitochondria burn passes through NAD+ cycling multiple times. This is why NAD+ depletion is felt as reduced energy — the biochemistry of energy production is literally running with reduced resources.

Metabolic health is the most studied application — specifically insulin sensitivity, fat metabolism, and the metabolic dysfunctions associated with aging and obesity. Multiple research groups have shown that restoring NAD+ levels in aged or metabolically stressed animal models improves glucose tolerance, fat oxidation, and mitochondrial function.

Cognitive aging research has examined NAD+ in models of age related cognitive decline and in neurodegenerative disease models. The brain is one of the most NAD+-dependent organs — neurons have extremely high energy requirements and are particularly vulnerable to NAD+ depletion. Cardiovascular health, muscle function, and exercise capacity have also been studied in NAD+ restoration research.

David Sinclair's laboratory at Harvard and Charles Brenner's group have published extensively on NAD+ aging biology, establishing the scientific foundation for the NAD+ research explosion of the past decade. Their work placed NAD+ at the intersection of mitochondrial function, sirtuin biology, DNA repair, and the hallmarks of aging.

Researchers studying NAD+ biology have studied both the direct molecule and compounds that the body converts into NAD+. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors — they are one or two enzymatic steps away from becoming NAD+.

The research strategy for precursors is straightforward: some cell types may be better at converting precursors to NAD+ than they are at importing NAD+ directly. By providing the precursor form, researchers can potentially raise intracellular NAD+ more efficiently in certain tissue types. The debate over which form is most effective in which context is an active area of research.

This catalog features NAD+ in its direct form for researchers who want to study the molecule itself — either systemically or in direct tissue research contexts where precursor conversion is not the relevant variable.

NAD+ itself is studied via IV administration in clinical research contexts, where rapid elevation of systemic NAD+ levels is desired. Subcutaneous administration in preclinical models has also been studied. Published clinical NAD+ IV protocols typically administer 500 mg to 1000 mg per session over a period of hours.

In preclinical research, intraperitoneal administration has been the most common route in rodent studies, with typical doses ranging from 200 to 500 mg/kg in metabolic research designs. Protocol durations range from single sessions to multi month chronic administration depending on the research question.

Researchers in this space are currently engaged in active debate about optimal dosing, administration frequency, and the relative merits of direct NAD+ versus precursor approaches. The primary literature reflects ongoing investigation rather than settled consensus.

NAD+ is available in the research catalog with full specifications. As a relatively small molecule (663.4 Da) compared to most research peptides, its identity and purity are straightforward to verify by standard analytical methods. The batch specific COA confirms HPLC purity and mass spectrometry identity.

NAD+ is highly water soluble and stable in lyophilized form. Storage requirements are standard: refrigerated, protected from moisture and light. The product page provides full reconstitution guidance for IV and subcutaneous research applications.

Researchers new to NAD+ biology should start with the foundational Sinclair and Guarente laboratories' papers on sirtuins and NAD+ aging biology before reviewing the clinical trial literature.